SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McClure Matthew W.
(Last) (First) (Middle)
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $16.18 02/27/2024 D 255,626 01/01/2021 12/01/2030 Common Stock 255,626 $0(1) 0 D
Stock Option (Right to Buy) $3.06 02/27/2024 D 92,000 03/04/2022 02/04/2032 Common Stock 92,000 $0(2) 0 D
Stock Option (Right to Buy) $3.06 02/27/2024 D 23,000 02/04/2025 02/04/2032 Common Stock 23,000 $0(3) 0 D
Stock Option (Right to Buy) $0.96 02/28/2024 A 75,183 (4) 12/01/2030 Common Stock 75,183 $0(1) 75,183 D
Stock Option (Right to Buy) $0.96 02/28/2024 A 65,713 (5) 02/04/2032 Common Stock 65,713 $0(2) 65,713 D
Stock Option (Right to Buy) $0.96 02/28/2024 A 16,428 (4) 02/04/2032 Common Stock 16,428 $0(3) 16,428 D
Explanation of Responses:
1. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share.
2. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share.
3. On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share.
4. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.
5. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date.
/s/ Lesley Ann Calhoun, as attorney-in fact for Matthew W. McClure 02/28/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aligos Therapeutics Charts.
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aligos Therapeutics Charts.